PMID- 37576547
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230815
IS  - 1756-2856 (Print)
IS  - 1756-2864 (Electronic)
IS  - 1756-2856 (Linking)
VI  - 16
DP  - 2023
TI  - mTOR pathway - a potential therapeutic target in stroke.
PG  - 17562864231187770
LID - 10.1177/17562864231187770 [doi]
LID - 17562864231187770
AB  - Stroke is ranked as the second leading cause of death worldwide and a major cause 
      of long-term disability. A potential therapeutic target that could offer 
      favorable outcomes in stroke is the mammalian target of rapamycin (mTOR) pathway. 
      mTOR is a serine/threonine kinase that composes two protein complexes, mTOR 
      complex 1 (mTORC1) and mTOR complex 2 (mTORC2), and is regulated by other 
      proteins such as the tuberous sclerosis complex. Through a significant number of 
      signaling pathways, the mTOR pathway can modulate the processes of post-ischemic 
      inflammation and autophagy, both of which play an integral part in the 
      pathophysiological cascade of stroke. Promoting or inhibiting such processes 
      under ischemic conditions can lead to apoptosis or instead sustained viability of 
      neurons. The purpose of this review is to examine the pathophysiological role of 
      mTOR in acute ischemic stroke, while highlighting promising neuroprotective 
      agents such as hamartin for therapeutic modulation of this pathway. The 
      therapeutic potential of mTOR is also discussed, with emphasis on implicated 
      molecules and pathway steps that warrant further elucidation in order for their 
      neuroprotective properties to be efficiently tested in future clinical trials.
CI  - (c) The Author(s), 2023.
FAU - Melanis, Konstantinos
AU  - Melanis K
AUID- ORCID: 0000-0002-3224-3053
AD  - Second Department of Neurology, School of Medicine and 'Attikon' University 
      Hospital, National and Kapodistrian University of Athens, Rimini 1 Chaidari, 
      Athens 12462, Greece.
AD  - Center of Basic Research, Biomedical Research Foundation of the Academy of 
      Athens, Athens, Greece.
FAU - Stefanou, Maria-Ioanna
AU  - Stefanou MI
AUID- ORCID: 0000-0002-2305-6627
AD  - Second Department of Neurology, School of Medicine and 'Attikon' University 
      Hospital, National and Kapodistrian University of Athens, Athens, Greece.
FAU - Themistoklis, Konstantinos M
AU  - Themistoklis KM
AD  - Center of Basic Research, Biomedical Research Foundation of the Academy of 
      Athens, Athens, Greece.
AD  - Department of Neurosurgery, 'Korgialenio, Benakio, H.R.C'. General Hospital of 
      Athens, Athens, Greece.
FAU - Papasilekas, Themistoklis
AU  - Papasilekas T
AD  - Center of Basic Research, Biomedical Research Foundation of the Academy of 
      Athens, Athens, Greece.
AD  - Department of Neurosurgery, 'Korgialenio, Benakio, H.R.C'. General Hospital of 
      Athens, Athens, Greece.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20230809
PL  - England
TA  - Ther Adv Neurol Disord
JT  - Therapeutic advances in neurological disorders
JID - 101480242
PMC - PMC10413897
OTO - NOTNLM
OT  - mTOR pathway
OT  - neuroprotection
OT  - stroke
OT  - tuberous sclerosis complex
COIS- The authors declared no potential conflicts of interest with respect to the 
      research, authorship, and/or publication of this article.
EDAT- 2023/08/14 06:42
MHDA- 2023/08/14 06:43
PMCR- 2023/08/09
CRDT- 2023/08/14 04:44
PHST- 2022/12/23 00:00 [received]
PHST- 2023/06/27 00:00 [accepted]
PHST- 2023/08/14 06:43 [medline]
PHST- 2023/08/14 06:42 [pubmed]
PHST- 2023/08/14 04:44 [entrez]
PHST- 2023/08/09 00:00 [pmc-release]
AID - 10.1177_17562864231187770 [pii]
AID - 10.1177/17562864231187770 [doi]
PST - epublish
SO  - Ther Adv Neurol Disord. 2023 Aug 9;16:17562864231187770. doi: 
      10.1177/17562864231187770. eCollection 2023.